Dxcover Platform - Pancreatic Cancer
Detection of pancreatic cancer
Pre-clinical/Clinical ValidationActive
Key Facts
Indication
Detection of pancreatic cancer
Phase
Pre-clinical/Clinical Validation
Status
Active
Company
About Dxcover
Dxcover is pioneering a multi-cancer early detection platform that leverages infrared spectroscopy and artificial intelligence to analyze liquid biopsy samples. Founded in 2016 and based in Glasgow, the company's technology aims to detect cancer at earlier, more treatable stages by identifying spectral biomarkers in blood serum. Its primary strategic application is the triage of high-risk patient populations, with brain tumors as the lead indication, followed by pancreatic and ovarian cancers. Dxcover is a private, pre-revenue company seeking partnerships and investment to advance its platform through clinical validation and regulatory pathways.
View full company profile